Venus Remedies has obtained permission from the Drug Controller General of India for conducting Phase III clinical trials of the new formulation developed by its research and development wing.
The company has begun multi-centred Phase III clinical trials for its new formulation, fixed dose combination drug of latest generation Cephalosporin with an Amino-glycoside, immediately after receiving this permission, Venus Remedies informed the Bombay Stock Exchange on Tuesday.
This product provides total solution for the treatment of life-threatening infections caused by multi resistant P. aeruginosa or Acinetobacter species, it said.
The formulation should be ready for commercial launch by December 2005. A patent application for the same has already been filed with the Indian Patent Office by the IPR division of the company, it said.
